Patent intelligence · US
US 11639355
Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
Patent details — US 11639355
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 2, 2023
- Expiration
- Apr 27, 2043
- Applicant
- Medshine Discovery Inc.
- Claims
- 15
- CPC classes
- A61P, A61P31/04, A61P31/12, A61P35/00
Quick answer
US 11639355 (Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors) is held by Medshine Discovery Inc.. Status: granted. Granted May 2, 2023. Expires Apr 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Medshine Discovery Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61P, A61P31/04, A61P31/12, A61P35/00, A61P35/02
More from Medshine Discovery Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 11639355?
US 11639355 (Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors) is held by Medshine Discovery Inc.. Status: granted. Granted May 2, 2023. Expires Apr 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11639355?
Medshine Discovery Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 11639355 expire?
Our index shows an expiration date of Apr 27, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.